Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications

Inclusion Criteria

• •Patients, who eligible to sign informed consent;
• •Patients with indications to lipid lowing therapy, according to local product document.
• •Patients with CHD and high risk of CV complications (Diabetes Mellitus II, Myocardial Infarction, Heart Failure, Arterial Hypertension, ets) will be included into study;
• •Patients with LDL levels: \> 3,5 mmol/l